Developer docs
API playgroundTry for free, no card

Search company profiles

Macrogen

Full company profile

uuid0008ply

Namestring
Macrogen
Legal namestring
Macrogen, Inc.
Websiteurl
macrogen.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Macrogen, Inc. is a Seoul-headquartered genomics and AI precision medicine company founded in 1997 and publicly listed on KOSDAQ (ticker 34450). The company provides fee-for-service genomic analysis to research institutions, pharmaceutical and biotech companies, healthcare providers, and direct-to-consumer customers across 153 countries, operating regional subsidiaries in Japan, Singapore, the Netherlands, Spain, Italy, France, Poland, Switzerland, the United States (Psomagen), and Chile. Its service portfolio spans the full multi-omics stack — next-generation sequencing (whole genome, exome, transcriptome, epigenome, metagenome, single-cell), capillary electrophoresis (Sanger) sequencing, microarray, oligo and gene synthesis, CRISPR model services, Olink proteomics, and spatial multi-omics — alongside clinical diagnostic services (PMG Lab NGS gene panels, cancer genome testing, GCLP-compliant clinical trial specimen analysis) and consumer brands GenTok and myPETGENE.

The underlying technology rests on 27+ years of accumulated sequencing know-how, 100PB+ of big-data computing infrastructure, and proprietary assets including the Korean Reference Genome AK1 (published in Nature, 2016). Macrogen claims CAPA Global Top 5 ranking by annual genome analysis volume, processes approximately 300,000 genomes per year, and holds the #1 domestic market share in Korea. The technology stack integrates instruments and reagents from a deep partner ecosystem (Illumina, Thermo Fisher, 10x Genomics, PacBio, Oxford Nanopore, Olink, Agilent, Ultima Genomics, Twist, Microsoft), and the company was the first global CRO to commit to deploying 10x Genomics Atera spatial biology instruments in 2026.

Revenue mechanics are predominantly transactional: per-base, per-reaction, per-sample, or quote-based project pricing for sequencing services, with multi-currency billing (USD, EUR, JPY, AUD, GBP, SGD) through a self-service LIMS platform (dna.macrogen.com) and regional enterprise field sales targeting large pharma and government contracts. The largest single revenue driver currently is the Korea National Integrated Bio Big Data Construction project (sole contractor; 145,952 WGS and 2,800 transcriptomes by 2026, scaling to 1 million Koreans by 2032). The company is transitioning its identity from a sequencing CRO toward an AI precision medicine platform, anchored by the Songdo Global Genome Center (completed June 2026), four internal R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data Institute for Health), and selection for the national Agentic AI customized-care project in 2025.

Short descriptiontext

Macrogen is a Seoul-based publicly traded (KOSDAQ: 34450) genomics CRO founded in 1997, providing fee-for-service NGS, Sanger, microarray, single-cell, spatial, and proteomics analysis to 33,000+ research, pharma, clinical, and consumer customers across 153 countries, now pivoting toward AI precision medicine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic sequencing services, next-generation sequencing, multi-omics analysis, precision medicine diagnostics, oligo and gene synthesis
Industry4 codes
PRIMARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomic Sequencing and Bioinformatics Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Fee-for-Service Genomic Sequencing and Analysis
TypeTransaction Fee
Description

Macrogen's primary revenue stream is fee-for-service genomic sequencing and analysis, encompassing NGS (Whole Genome, Exome, Transcriptome, Metagenome, Epigenome), CES/Sanger sequencing, microarray, and oligo/gene synthesis services billed per reaction, sample, or project.

macrogen.com
2Clinical Diagnostic Services
TypeTransaction Fee
Description

Revenue from precision medicine cancer genome testing, NGS gene panel diagnostics (PMG Lab), and GCLP clinical trial sample analysis services, billed per test or contract.

macrogen.com
3Personal Healthcare and Wellness Services
TypeTransaction Fee
Description

Direct-to-consumer genetic testing services (GenTok brand) for disease prediction, microbiome analysis, and pet genetic health testing, billed per test kit or analysis.

macrogen.com
4Laboratory Consumables and Reagents
TypeHardware Sales
Description

Sale of research reagents, labware, and related consumables supporting genomic research workflows.

macrogen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Pricing details6 tiers
1Standard Oligo DNA Synthesis — priced per base (mer)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard Oligo DNA: $0.15–$1.00 USD per base (0.025–1 µmole scale); MOPC purification included free; HPLC/PAGE purification: $20–$30 per oligo. EUR pricing: €0.14–€0.95 per base. Length limit: 3–130 mer for standard oligos.

dna.macrogen.com
2Modified Oligo Synthesis — priced per base plus modification fee
ModelUnit PricingBilling cadencePay-as-you-go
Notes

5' Fluorescent modifications (FAM, HEX, TET, CY3, CY5, etc.): $30–$380 per oligo. Dual-labeled probes (e.g., FAM-TAMRA, CY3-BHQ1): $145–$475. MGB probes: $430–$850. Internal modifications (LNA, Phosphorothioate, CY3/CY5): $3–$120 per base.

dna.macrogen.com
3RNA Oligo Synthesis — priced per base
ModelUnit PricingBilling cadencePay-as-you-go
Notes

RNA base: $4–$8 per base (10–50 nmole); 2'-O-Methyl: $8–$20; 2'-Fluoro: $35–$60; LNA: $30–$50. HPLC purification: $30–$50 additional.

dna.macrogen.com
4Custom Peptide Synthesis — priced per peptide based on length and purity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Custom peptides (3 mg, 85–95% purity): $77–$681 depending on length (2–40 mer). Modification peptides with fluorescent labels (TAMRA, CY3, CY5): $150–$1,845 additional. EUR pricing also available.

dna.macrogen.com
5CES (Sanger) Sequencing Services — priced per reaction or plate
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard Sequencing available as single reaction or 96-well plate. Difficult Sequencing, Primer Walking (500–800 bp extension per direction, ~4 days), EZ-Seq, and Customized PCR/Sequencing services available. SNP & Mutation Analysis, NGS Validation, and PCR Optimization offered as bundled services. Results within 48 hours for standard sequencing.

dna.macrogen.com
6NGS Services — project-based quotation
ModelUsage-basedBilling cadencePay-as-you-go
Notes

NGS services (Whole Genome, Exome, Transcriptome, Epigenome, Metagenome, Targeted, Single Cell RNA) are quote-based, with pricing dependent on species, genome size, sequencing depth, platform, and analysis requirements. Quotation requests via dna.macrogen.com.

macrogen.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Psomagen
Description

US subsidiary of Macrogen providing genomic analysis services as a global CRO

macrogen.com
+4 more records
Core offering1 text field

Macrogen is a global genomics and AI healthcare company that provides fee-for-service genomic sequencing, multi-omics analysis, and bioinformatics interpretation. Its portfolio spans NGS (whole genome, exome, transcriptome, epigenome, metagenome), CES/Sanger sequencing, microarray, proteomics (Olink), gene and oligo synthesis, single-cell and spatial multi-omics, and clinical diagnostics including cancer genome testing and GCLP-compliant clinical trial analysis. It also operates consumer genetic testing platforms (GenTok, myPETGENE) and runs AI-driven disease prediction models integrating genomic, clinical, and lifestyle data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Annual genome analysis capacity of 300,000 genomes per year
+3 more records
Product overview1 text field

Macrogen is a global genomics and AI healthcare company offering a comprehensive suite of genomic analysis services organized around three core pillars: research analysis services, clinical diagnostic services, and consumer health platforms. The research portfolio includes NGS-based services (Whole Genome Sequencing, Whole Exome Sequencing, Transcriptome Sequencing, Epigenome Sequencing, Metagenome Sequencing), CES/Sanger sequencing, microarray services, proteomics (Olink), gene synthesis, oligo synthesis, CRISPR/model animal services, single-cell multi-omics, spatial multi-omics, and microbiome analysis. The clinical division provides precision medicine cancer services, cancer genome testing with NGS gene panels (PMG Lab), and GCLP-compliant clinical trial specimen analysis. Consumer-facing services include GenTok direct-to-consumer genetic testing and myPETGENE pet healthcare. The company operates R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data) and strategic facilities including the Songdo Global Genome Center AI precision medicine hub. Recent launches include deployment of the 10x Genomics Atera spatial biology platform (2026) and a Singapore genomics laboratory via PacBio partnership (2025).

Product and service20 records
1Whole Genome Sequencing
CategoryGenomic Sequencing (NGS)
Description

DNA sequencing service that reads and analyzes the entire genome, including Whole Genome De novo Sequencing for new species and Whole Genome Resequencing for variation analysis such as SNP, InDel, CNV, and structural variation, for research institutions and pharma clients.

2Whole Exome Sequencing
CategoryGenomic Sequencing (NGS)
Description

Selective analysis of exon regions where genes are located, providing a cost-effective alternative to whole genome resequencing for gene variation analysis in research and clinical research contexts.

3Transcriptome Sequencing
CategoryGenomic Sequencing (NGS)
Description

RNA sequencing service for gene expression profiling, novel transcriptome discovery, fusion gene detection, and alternative splicing variant analysis, including mRNA, single-cell RNA, small RNA, and exosomal RNA sequencing, for researchers.

4Epigenome Sequencing
CategoryGenomic Sequencing (NGS)
Description

Sequencing service analyzing DNA methylation and histone acetylation patterns, including Whole Genome Bisulfite Sequencing and Methyl-Capture Sequencing, for epigenetic mechanism research in academic and commercial settings.

5Metagenome Sequencing
6CES (Capillary Electrophoresis Sequencing)
CategoryCapillary Electrophoresis (Sanger) Sequencing
Description

Sanger DNA sequencing service including Standard Sequencing, Difficult Sequencing, Primer Walking, and EZ-Seq, along with identification services, fragment analysis, and customized sequencing, for researchers globally with per-reaction pricing.

7Microarray Services
CategoryMicroarray Analysis
Description

DNA microarray-based gene expression, SNP genotyping, CGH for copy number variation, and DNA methylation analysis using Illumina, Affymetrix, and Agilent platforms, for research and clinical research clients.

8Proteomics (Olink)
CategoryProteomics
Description

High-sensitivity protein analysis service using Olink technology for biomarker discovery and protein expression profiling, integrated with genomic and transcriptomic data for multi-omics research clients.

9Gene Synthesis
CategoryGene Synthesis
Description

DNA gene synthesis service synthesizing genes in plasmid DNA state with free cloning, 100% sequence guarantee via ABI 3730xl, and additional mutagenesis services, for researchers requiring custom genetic constructs.

10Oligo Synthesis
CategoryOligo Synthesis
Description

DNA, RNA, and peptide oligo synthesis service with automated processes, various modification options, and quality control via MALDI-TOF mass spectrometry, for research laboratories globally.

11CRISPR/Model Animal Services
CategoryModel Organism Services
Description

CRISPR Knock-in/out services, genetically engineered mouse (GEM) models, mass production, and mouse model services for academic and pharmaceutical research applications.

12Single Cell Multi-omics Analysis
CategorySingle-Cell Multi-Omics
Description

Single-cell level analysis of gene expression enabling analysis of thousands of transcription bodies simultaneously, including B cell and T cell full-length clonotype analysis, for translational and discovery research.

13Spatial Multi-Omics Analysis
CategorySpatial Multi-Omics
Description

In situ spatial biology analysis for whole-transcriptome spatial analysis at single-cell sensitivity, including the 10x Genomics Atera platform deployment, supporting fresh-frozen and FFPE tissue samples for discovery and translational research.

14Precision Medicine (Cancer)
CategoryClinical Diagnostics
Description

Cancer risk prediction, cancer cause analysis, and cancer monitoring services based on genomic information integrated with medical and lifestyle data, for hospitals and clinical partners.

15Cancer Genome Testing
CategoryClinical Diagnostics
Description

Comprehensive cancer genetic testing including cancer gene panels, hereditary cancer susceptibility testing, BRCA1/2 testing, and gastric cancer panel, for hospitals and healthcare providers.

16NGS Gene Panel Laboratory (PMG Lab)
17GCLP Clinical Trial Specimen Analysis
18Personal Healthcare (GenTok)
19Pet Healthcare (myPETGENE)
20Microbiome Analysis Service
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-19
Description

Macrogen and its US subsidiary Psomagen committed to deploying multiple 10x Genomics Atera instruments as the first global CRO/service provider to adopt the Atera spatial biology platform, enabling whole-transcriptome spatial analysis at scale for discovery and translational research. Commercial shipments expected in H2 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-03
Description

Macrogen and Ultima Genomics jointly held a symposium in Seoul to promote AI genomic analysis and the development of an integrated BioAI ecosystem. The event focused on leveraging the UG200 platform to reduce costs and increase efficiency in genomic data production and analysis for personalized medicine and disease prediction.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Pacific Biosciences partnered with A*STAR and Macrogen Inc. to launch a high-precision genomics laboratory in Singapore. The partnership aims to advance precision medicine research in the Asia-Pacific region, leveraging PacBio SMRT sequencing technology alongside Macrogen's genomic analysis capabilities.

Strategic tierMajorTypeTechnology or Integration
Description

Illumina is listed as a global partner logo on Macrogen's website. Macrogen uses Illumina platforms including NovaSeq X plus, NovaSeq 6000, HiSeq X ten, HiSeq 4000, HiSeq 2500, NextSeq 500, and MiSeq for various NGS applications.

Strategic tierMajorTypeTechnology or Integration
Description

Thermo Fisher Scientific is listed as a global partner logo on Macrogen's website. Macrogen utilizes Thermo Fisher platforms for various sequencing and analysis applications.

Strategic tierMajorTypeTechnology or Integration
Description

Olink is listed as a global partner logo. Macrogen offers Olink-based high-sensitivity proteomics analysis services, providing biomarker discovery and protein biomarker analysis.

Strategic tierMajorTypeTechnology or Integration
Description

Agilent is listed as a global partner logo. Macrogen uses Agilent platforms including SurePrint G3 Gene Expression, SurePrint G3 Exome microarrays, and Agilent CGH microarrays for gene expression and copy number variation analysis.

Strategic tierMajorTypeTechnology or Integration
Description

Oxford Nanopore Technologies is listed as a global partner logo. Macrogen leverages nanopore sequencing technology for long-read genomic analysis applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

A*STAR partnered with Pacific Biosciences and Macrogen to launch a high-precision genomics laboratory in Singapore, advancing precision medicine research in the Asia-Pacific region within the Singapore National Precision Medicine programme.

10DNA Link
Strategic tierMajorTypeStrategic or Co-development Partner
Description

DNA Link is a consortium partner with Macrogen, Teragen Biotech, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, led by the Ministry of Health and Welfare and Korea Disease Control and Prevention Agency.

macrogen.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Teragen Biotech is a consortium partner with Macrogen, DNA Link, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, responsible for producing genomic and transcriptomic data for 1 million Koreans.

12CZEN Biovitz
Strategic tierMajorTypeStrategic or Co-development Partner
Description

CZEN Biovitz is a consortium partner with Macrogen, DNA Link, and Teragen Biotech in Korea's National Integrated Bio Big Data Construction project.

macrogen.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest global genomic sequencing service provider with massive population-genomics project experience (e.g., Chinese Million Genomes). Directly competes with Macrogen on NGS services, NIPT and clinical genomics, and on government-scale population genomics contracts across Asia.

TypeDirect peer
Description

Global NGS services CRO offering whole genome, exome, transcriptome and single-cell sequencing from facilities in the US, Europe and China. Directly comparable to Macrogen's core fee-for-service NGS portfolio and target academic/biopharma customer base.

TypeDirect peer
Description

Provides genomic services including Sanger/NGS, gene synthesis and oligo synthesis globally from US, European and Asian labs. Overlaps with Macrogen's CES, oligo and gene synthesis product lines and similar pharma/biotech customer base.

TypeDirect peer
Description

Global genomics services arm of Eurofins Scientific offering NGS, Sanger, microarray, oligo synthesis and synthetic biology services. Directly comparable fee-for-service genomics portfolio and customer segments across Europe, US and Asia.

TypeDirect peer
Description

US-based NGS services company specializing in whole-genome sequencing for immuno-oncology clinical trials and biopharma customers. Comparable on pharma GCLP/clinical-trial specimen analysis and on pushing into AI-driven molecular diagnostics.

TypeBroad incumbent
Description

Dominant NGS instrument and reagent provider whose platforms (NovaSeq, NextSeq) underpin most of Macrogen's service volume. Increasingly a broad incumbent offering its own population-genomics and clinical sequencing services, posing both partner and competitive risk.

TypeDirect peer
Description

Major provider of custom oligonucleotides, gene synthesis and NGS library prep reagents/services. Directly overlaps with Macrogen's oligo synthesis, gene synthesis and reagent product lines, particularly in the US and European research market.

TypeEmerging player
Description

Synthetic DNA and NGS target-enrichment provider serving pharma, biotech and academic customers. Overlaps with Macrogen's gene/oligo synthesis and emerging NGS panel services, and is itself a Macrogen technology partner.

9Tempus AI
TypeBroad incumbent
Description

AI-driven precision medicine company combining multi-modal data with sequencing and analytics for oncology. Comparable to Macrogen's AI precision medicine and cancer genome testing ambitions, but operating at much larger scale in the US market.

TypeBroad incumbent
Description

Clinical genomics leader offering comprehensive genomic profiling for oncology. Comparable to Macrogen's PMG Lab cancer genome testing and NGS gene panel business, particularly for pharma companion-diagnostic and clinical-trial biomarker programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Macrogen

Genomic Sequencing and Bioinformatics Servicesmacrogen.com

Macrogen is a Seoul-based publicly traded (KOSDAQ: 34450) genomics CRO founded in 1997, providing fee-for-service NGS, Sanger, microarray, single-cell, spatial, and proteomics analysis to 33,000+ research, pharma, clinical, and consumer customers across 153 countries, now pivoting toward AI precision medicine.

What Macrogen does

Macrogen, Inc. is a Seoul-headquartered genomics and AI precision medicine company founded in 1997 and publicly listed on KOSDAQ (ticker 34450). The company provides fee-for-service genomic analysis to research institutions, pharmaceutical and biotech companies, healthcare providers, and direct-to-consumer customers across 153 countries, operating regional subsidiaries in Japan, Singapore, the Netherlands, Spain, Italy, France, Poland, Switzerland, the United States (Psomagen), and Chile. Its service portfolio spans the full multi-omics stack — next-generation sequencing (whole genome, exome, transcriptome, epigenome, metagenome, single-cell), capillary electrophoresis (Sanger) sequencing, microarray, oligo and gene synthesis, CRISPR model services, Olink proteomics, and spatial multi-omics — alongside clinical diagnostic services (PMG Lab NGS gene panels, cancer genome testing, GCLP-compliant clinical trial specimen analysis) and consumer brands GenTok and myPETGENE.

The underlying technology rests on 27+ years of accumulated sequencing know-how, 100PB+ of big-data computing infrastructure, and proprietary assets including the Korean Reference Genome AK1 (published in Nature, 2016). Macrogen claims CAPA Global Top 5 ranking by annual genome analysis volume, processes approximately 300,000 genomes per year, and holds the #1 domestic market share in Korea. The technology stack integrates instruments and reagents from a deep partner ecosystem (Illumina, Thermo Fisher, 10x Genomics, PacBio, Oxford Nanopore, Olink, Agilent, Ultima Genomics, Twist, Microsoft), and the company was the first global CRO to commit to deploying 10x Genomics Atera spatial biology instruments in 2026.

Revenue mechanics are predominantly transactional: per-base, per-reaction, per-sample, or quote-based project pricing for sequencing services, with multi-currency billing (USD, EUR, JPY, AUD, GBP, SGD) through a self-service LIMS platform (dna.macrogen.com) and regional enterprise field sales targeting large pharma and government contracts. The largest single revenue driver currently is the Korea National Integrated Bio Big Data Construction project (sole contractor; 145,952 WGS and 2,800 transcriptomes by 2026, scaling to 1 million Koreans by 2032). The company is transitioning its identity from a sequencing CRO toward an AI precision medicine platform, anchored by the Songdo Global Genome Center (completed June 2026), four internal R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data Institute for Health), and selection for the national Agentic AI customized-care project in 2025.

Macrogen firmographics

Firmographics
Name
Macrogen
Legal name
Macrogen, Inc.
Website
https://macrogen.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
Macrogen is a Seoul-based publicly traded (KOSDAQ: 34450) genomics CRO founded in 1997, providing fee-for-service NGS, Sanger, microarray, single-cell, spatial, and proteomics analysis to 33,000+ research, pharma, clinical, and consumer customers across 153 countries, now pivoting toward AI precision medicine.
Ownership category
akta.pro rank

Macrogen industry classification

Industry
Product category
Genomic Sequencing and Bioinformatics Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Genomic sequencing services
  • Next-generation sequencing
  • Multi-omics analysis
  • Precision medicine diagnostics
  • Oligo and gene synthesis

Where Macrogen is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices15 records

Markets served

Macrogen business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Fee-for-Service Genomic Sequencing and Analysis: Macrogen's primary revenue stream is fee-for-service genomic sequencing and analysis, encompassing NGS (Whole Genome, Exome, Transcriptome, Metagenome, Epigenome), CES/Sanger sequencing, microarray, and oligo/gene synthesis services billed per reaction, sample, or project.
  2. Clinical Diagnostic Services: Revenue from precision medicine cancer genome testing, NGS gene panel diagnostics (PMG Lab), and GCLP clinical trial sample analysis services, billed per test or contract.
  3. Personal Healthcare and Wellness Services: Direct-to-consumer genetic testing services (GenTok brand) for disease prediction, microbiome analysis, and pet genetic health testing, billed per test kit or analysis.
  4. Laboratory Consumables and Reagents: Sale of research reagents, labware, and related consumables supporting genomic research workflows.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Oligo DNA Synthesis — priced per base (mer)
Unit PricingPay-as-you-goModified Oligo Synthesis — priced per base plus modification fee
Unit PricingPay-as-you-goRNA Oligo Synthesis — priced per base
Unit PricingPay-as-you-goCustom Peptide Synthesis — priced per peptide based on length and purity
Unit PricingPay-as-you-goCES (Sanger) Sequencing Services — priced per reaction or plate
Usage-basedPay-as-you-goNGS Services — project-based quotation

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Macrogen product offering

Product offering

Core offering

Macrogen is a global genomics and AI healthcare company that provides fee-for-service genomic sequencing, multi-omics analysis, and bioinformatics interpretation. Its portfolio spans NGS (whole genome, exome, transcriptome, epigenome, metagenome), CES/Sanger sequencing, microarray, proteomics (Olink), gene and oligo synthesis, single-cell and spatial multi-omics, and clinical diagnostics including cancer genome testing and GCLP-compliant clinical trial analysis. It also operates consumer genetic testing platforms (GenTok, myPETGENE) and runs AI-driven disease prediction models integrating genomic, clinical, and lifestyle data.

Product overview

Macrogen is a global genomics and AI healthcare company offering a comprehensive suite of genomic analysis services organized around three core pillars: research analysis services, clinical diagnostic services, and consumer health platforms. The research portfolio includes NGS-based services (Whole Genome Sequencing, Whole Exome Sequencing, Transcriptome Sequencing, Epigenome Sequencing, Metagenome Sequencing), CES/Sanger sequencing, microarray services, proteomics (Olink), gene synthesis, oligo synthesis, CRISPR/model animal services, single-cell multi-omics, spatial multi-omics, and microbiome analysis. The clinical division provides precision medicine cancer services, cancer genome testing with NGS gene panels (PMG Lab), and GCLP-compliant clinical trial specimen analysis. Consumer-facing services include GenTok direct-to-consumer genetic testing and myPETGENE pet healthcare. The company operates R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data) and strategic facilities including the Songdo Global Genome Center AI precision medicine hub. Recent launches include deployment of the 10x Genomics Atera spatial biology platform (2026) and a Singapore genomics laboratory via PacBio partnership (2025).

Differentiator

Problem solved

Functional benefit

Brands

  • Psomagen: US subsidiary of Macrogen providing genomic analysis services as a global CRO
  • GenTok (젠톡)
  • myPETGENE ID
  • Songdo Global Genome Center
  • PMG Lab

Products and services

  • Whole Genome Sequencing DNA sequencing service that reads and analyzes the entire genome, including Whole Genome De novo Sequencing for new species and Whole Genome Resequencing for variation analysis such as SNP, InDel, CNV, and structural variation, for research institutions and pharma clients.
  • Whole Exome Sequencing Selective analysis of exon regions where genes are located, providing a cost-effective alternative to whole genome resequencing for gene variation analysis in research and clinical research contexts.
  • Transcriptome Sequencing RNA sequencing service for gene expression profiling, novel transcriptome discovery, fusion gene detection, and alternative splicing variant analysis, including mRNA, single-cell RNA, small RNA, and exosomal RNA sequencing, for researchers.
  • Epigenome Sequencing Sequencing service analyzing DNA methylation and histone acetylation patterns, including Whole Genome Bisulfite Sequencing and Methyl-Capture Sequencing, for epigenetic mechanism research in academic and commercial settings.
  • Metagenome Sequencing
  • CES (Capillary Electrophoresis Sequencing) Sanger DNA sequencing service including Standard Sequencing, Difficult Sequencing, Primer Walking, and EZ-Seq, along with identification services, fragment analysis, and customized sequencing, for researchers globally with per-reaction pricing.
  • Microarray Services DNA microarray-based gene expression, SNP genotyping, CGH for copy number variation, and DNA methylation analysis using Illumina, Affymetrix, and Agilent platforms, for research and clinical research clients.
  • Proteomics (Olink) High-sensitivity protein analysis service using Olink technology for biomarker discovery and protein expression profiling, integrated with genomic and transcriptomic data for multi-omics research clients.
  • Gene Synthesis DNA gene synthesis service synthesizing genes in plasmid DNA state with free cloning, 100% sequence guarantee via ABI 3730xl, and additional mutagenesis services, for researchers requiring custom genetic constructs.
  • Oligo Synthesis DNA, RNA, and peptide oligo synthesis service with automated processes, various modification options, and quality control via MALDI-TOF mass spectrometry, for research laboratories globally.
  • CRISPR/Model Animal Services CRISPR Knock-in/out services, genetically engineered mouse (GEM) models, mass production, and mouse model services for academic and pharmaceutical research applications.
  • Single Cell Multi-omics Analysis Single-cell level analysis of gene expression enabling analysis of thousands of transcription bodies simultaneously, including B cell and T cell full-length clonotype analysis, for translational and discovery research.
  • Spatial Multi-Omics Analysis In situ spatial biology analysis for whole-transcriptome spatial analysis at single-cell sensitivity, including the 10x Genomics Atera platform deployment, supporting fresh-frozen and FFPE tissue samples for discovery and translational research.
  • Precision Medicine (Cancer) Cancer risk prediction, cancer cause analysis, and cancer monitoring services based on genomic information integrated with medical and lifestyle data, for hospitals and clinical partners.
  • Cancer Genome Testing Comprehensive cancer genetic testing including cancer gene panels, hereditary cancer susceptibility testing, BRCA1/2 testing, and gastric cancer panel, for hospitals and healthcare providers.
  • NGS Gene Panel Laboratory (PMG Lab)
  • GCLP Clinical Trial Specimen Analysis
  • Personal Healthcare (GenTok)
  • Pet Healthcare (myPETGENE)
  • Microbiome Analysis Service

Quantifiable outcome

  • Annual genome analysis capacity of 300,000 genomes per year
  • +3 more outcomes

Companies that use Macrogen

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles5 records

Macrogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Macrogen partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and major.

  • 10x GenomicscoreTechnology or Integration · 19 April 2026Macrogen and its US subsidiary Psomagen committed to deploying multiple 10x Genomics Atera instruments as the first global CRO/service provider to adopt the Atera spatial biology platform, enabling whole-transcriptome spatial analysis at scale for discovery and translational research. Commercial shipments expected in H2 2026.
  • Ultima GenomicscoreStrategic or Co-development Partner · 3 April 2026Macrogen and Ultima Genomics jointly held a symposium in Seoul to promote AI genomic analysis and the development of an integrated BioAI ecosystem. The event focused on leveraging the UG200 platform to reduce costs and increase efficiency in genomic data production and analysis for personalized medicine and disease prediction.
  • Pacific Biosciences (PacBio)coreStrategic or Co-development Partner · 1 January 2025Pacific Biosciences partnered with A*STAR and Macrogen Inc. to launch a high-precision genomics laboratory in Singapore. The partnership aims to advance precision medicine research in the Asia-Pacific region, leveraging PacBio SMRT sequencing technology alongside Macrogen's genomic analysis capabilities.
  • IlluminamajorTechnology or IntegrationIllumina is listed as a global partner logo on Macrogen's website. Macrogen uses Illumina platforms including NovaSeq X plus, NovaSeq 6000, HiSeq X ten, HiSeq 4000, HiSeq 2500, NextSeq 500, and MiSeq for various NGS applications.
  • Thermo Fisher ScientificmajorTechnology or IntegrationThermo Fisher Scientific is listed as a global partner logo on Macrogen's website. Macrogen utilizes Thermo Fisher platforms for various sequencing and analysis applications.
  • OlinkmajorTechnology or IntegrationOlink is listed as a global partner logo. Macrogen offers Olink-based high-sensitivity proteomics analysis services, providing biomarker discovery and protein biomarker analysis.
  • AgilentmajorTechnology or IntegrationAgilent is listed as a global partner logo. Macrogen uses Agilent platforms including SurePrint G3 Gene Expression, SurePrint G3 Exome microarrays, and Agilent CGH microarrays for gene expression and copy number variation analysis.
  • Oxford Nanopore TechnologiesmajorTechnology or IntegrationOxford Nanopore Technologies is listed as a global partner logo. Macrogen leverages nanopore sequencing technology for long-read genomic analysis applications.
  • A*STAR (Agency for Science, Technology and Research, Singapore)coreStrategic or Co-development PartnerA*STAR partnered with Pacific Biosciences and Macrogen to launch a high-precision genomics laboratory in Singapore, advancing precision medicine research in the Asia-Pacific region within the Singapore National Precision Medicine programme.
  • DNA LinkmajorStrategic or Co-development PartnerDNA Link is a consortium partner with Macrogen, Teragen Biotech, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, led by the Ministry of Health and Welfare and Korea Disease Control and Prevention Agency.
  • Teragen BiotechmajorStrategic or Co-development PartnerTeragen Biotech is a consortium partner with Macrogen, DNA Link, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, responsible for producing genomic and transcriptomic data for 1 million Koreans.
  • CZEN BiovitzmajorStrategic or Co-development PartnerCZEN Biovitz is a consortium partner with Macrogen, DNA Link, and Teragen Biotech in Korea's National Integrated Bio Big Data Construction project.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Macrogen competitors and assessment

Company assessment

Direct peers

  • BGI Group: Largest global genomic sequencing service provider with massive population-genomics project experience (e.g., Chinese Million Genomes). Directly competes with Macrogen on NGS services, NIPT and clinical genomics, and on government-scale population genomics contracts across Asia.
  • Novogene: Global NGS services CRO offering whole genome, exome, transcriptome and single-cell sequencing from facilities in the US, Europe and China. Directly comparable to Macrogen's core fee-for-service NGS portfolio and target academic/biopharma customer base.
  • Azenta Life Sciences (formerly GENEWIZ): Provides genomic services including Sanger/NGS, gene synthesis and oligo synthesis globally from US, European and Asian labs. Overlaps with Macrogen's CES, oligo and gene synthesis product lines and similar pharma/biotech customer base.
  • Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering NGS, Sanger, microarray, oligo synthesis and synthetic biology services. Directly comparable fee-for-service genomics portfolio and customer segments across Europe, US and Asia.
  • Personalis: US-based NGS services company specializing in whole-genome sequencing for immuno-oncology clinical trials and biopharma customers. Comparable on pharma GCLP/clinical-trial specimen analysis and on pushing into AI-driven molecular diagnostics.
  • Integrated DNA Technologies (IDT, Danaher): Major provider of custom oligonucleotides, gene synthesis and NGS library prep reagents/services. Directly overlaps with Macrogen's oligo synthesis, gene synthesis and reagent product lines, particularly in the US and European research market.

Broad incumbents

  • Illumina: Dominant NGS instrument and reagent provider whose platforms (NovaSeq, NextSeq) underpin most of Macrogen's service volume. Increasingly a broad incumbent offering its own population-genomics and clinical sequencing services, posing both partner and competitive risk.
  • Tempus AI: AI-driven precision medicine company combining multi-modal data with sequencing and analytics for oncology. Comparable to Macrogen's AI precision medicine and cancer genome testing ambitions, but operating at much larger scale in the US market.
  • Foundation Medicine (Roche): Clinical genomics leader offering comprehensive genomic profiling for oncology. Comparable to Macrogen's PMG Lab cancer genome testing and NGS gene panel business, particularly for pharma companion-diagnostic and clinical-trial biomarker programs.

Emerging players

  • Twist Bioscience: Synthetic DNA and NGS target-enrichment provider serving pharma, biotech and academic customers. Overlaps with Macrogen's gene/oligo synthesis and emerging NGS panel services, and is itself a Macrogen technology partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Macrogen social profiles

Digital presence

Macrogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Macrogen leadership team

Management profile

Number of profiles

Profiles4 records

Macrogen subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Macrogen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Macrogen M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macrogen

What does Macrogen do?

Macrogen is a global genomics and AI healthcare company that provides fee-for-service genomic sequencing, multi-omics analysis, and bioinformatics interpretation. Its portfolio spans NGS (whole genome, exome, transcriptome, epigenome, metagenome), CES/Sanger sequencing, microarray, proteomics (Olink), gene and oligo synthesis, single-cell and spatial multi-omics, and clinical diagnostics including cancer genome testing and GCLP-compliant clinical trial analysis. It also operates consumer genetic testing platforms (GenTok, myPETGENE) and runs AI-driven disease prediction models integrating genomic, clinical, and lifestyle data.

Is Macrogen a public or private company?

Macrogen is a public company. It is classified as public and is currently operating.

When was Macrogen founded?

Macrogen was founded in 1997. It employs 101 to 250 people.

Where is Macrogen based?

Macrogen is headquartered in Seoul, South Korea, in the Asia region.

How does Macrogen make money?

Four revenue lines are on record. Fee-for-Service Genomic Sequencing and Analysis are the primary driver. The others are clinical Diagnostic Services, personal Healthcare and Wellness Services and laboratory Consumables and Reagents.

Who are Macrogen's main competitors?

Direct peers on record are BGI Group, Novogene, Azenta Life Sciences (formerly GENEWIZ), Eurofins Genomics, Personalis and Integrated DNA Technologies (IDT, Danaher). Broad incumbents are Illumina, Tempus AI and Foundation Medicine (Roche). Twist Bioscience is listed as an emerging player.

Does Macrogen have an API?

No public API is recorded for Macrogen.

What industry is Macrogen in?

Macrogen's product category is Genomic Sequencing and Bioinformatics Services. Its primary akta.pro industry code is HLAGANAH, Microbiome & Metagenomics Services, with a secondary code of HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NaverMacrogen adopts Roche's next-gen platform to speed up genome sequencingMacrogen began operating Roche's Axelios 1 sequencing platform at its Songdo Global Genome Center in Incheon on Wednesday. The system uses Sequencing by Expansion technology to process DNA into Xpandomers, enabling faster and larger-scale genomic analysis. Macrogen plans to integrate it with its AI and automation systems to support population-scale studies.The Korea HeraldMacrogen adopts Roche's next-gen platform to speed up genome sequencingMacrogen began operating Roche's Axelios 1 sequencing platform at its Songdo Global Genome Center in Incheon. The system uses Sequencing by Expansion technology, enabling high-accuracy sequencing and greater data throughput. Macrogen plans to integrate it with existing automation and AI to speed up results and support large-scale genomic studies.BusinesskoreaFaith Village Foods 'Yogurt Run' collaborates with Macrogen to operate the second run ambassador program.Shinangchon Food and Macrogen launched a 90-day ambassador program for its 'Yogurt Run' fermented milk, selecting 30 runners from August 31 to September 5. Participants receive product batches, a microbiome test kit, and health lectures. The program runs from September 10 to December 9.SynBioBeta10x Genomics Unveils Atera and Sets a New Bar for Spatial Biology at Scale10x Genomics unveiled Atera, an in situ spatial biology platform for whole-transcriptome spatial analysis, at the AACR Annual Meeting in San Diego on April 18, 2026. The platform can run up to 800 whole-transcriptome samples per year on a single instrument at 1 square centimeter each, with early access partners including the Allen Institute, Brigham and Women's Hospital, and the German Cancer Research Center already generating data that has reshaped assumptions in cancer biology. Commercial adoption is underway, with Macrogen and its US subsidiary Psomagen committing to deploy multiple Atera instruments as the first global CRO on the platform, while Bioptimus plans to expand from Xenium to Atera in 2027 as part of its STELA spatial atlas program.GlobeNewswireOmics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com has released a market report projecting the omics-based clinical trials market to grow from $31.71 billion in 2025 to $47.78 billion by 2030, driven by precision medicine adoption, AI-enhanced patient recruitment, and regulatory acceptance of omics endpoints. Key strategic developments highlighted include Bruker Corporation's acquisition of Biocrates Life Sciences AG in June 2025 and Pacific Biosciences' partnership with A*STAR and Macrogen Inc. to launch a Singapore-based genomics laboratory. The report identifies North America as the current market leader with Asia-Pacific poised for rapid expansion, while noting that tariffs present challenges for imported sequencing tools, particularly affecting North America and Europe's pharmaceutical sectors.GlobeNewswireOmics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe omics-based clinical trials market is projected to grow from $31.71 billion in 2025 to $47.78 billion by 2030, driven by precision medicine adoption, AI-enhanced patient recruitment, and regulatory acceptance of omics endpoints. Bruker Corporation acquired Biocrates Life Sciences AG in June 2025 to strengthen its multi-omics offerings, while Pacific Biosciences partnered with A*STAR and Macrogen to launch a high-precision genomics facility in Singapore. North America currently leads the market, though Asia-Pacific is expected to experience rapid expansion, with tariffs on imported sequencing tools presenting challenges for pharmaceutical sectors in North America and Europe.VenturesquareMacrogen signs MOU for NGS-based precision medicine research collaboration with Chonnam National University HospitalMacrogen signed an MOU with Chonnam National University Hospital on the 8th to strengthen NGS-based precision medicine research. The agreement covers genomic analysis, technical consulting, joint research, and academic exchanges, aiming to improve research efficiency and data utilization. Macrogen plans to expand cooperation with other medical and research institutions.VenturesquareMacrogen and Ultima Genomics hold a joint symposium to popularize AI genomic analysis.Macrogen, a global AI genomics analysis company, co-hosted the 'BioAI and Genomics Analysis Symposium' with Ultima Genomics, Twist Bioscience, and the Korea Biotechnology Industry Association on October 2 at the Conrad Hotel in Seoul, South Korea. The event gathered approximately 40 key researchers and business leaders to showcase the synergy between Macrogen's genomic analysis capabilities and Ultima Genomics' ultra-high-throughput NGS platform UG200, which enables low-cost, high-efficiency genomic data production. The companies presented a vision to build an integrated BioAI ecosystem connecting data generation, AI analysis, and clinical application to accelerate the popularization of genomic analysis for disease prediction and personalized treatment.NewsweekHow Macrogen Is Democratizing GenomicsMacrogen has launched GenTok, a platform combining DNA testing and microbiome analysis with AI-powered health consultations, aiming to provide genetic services to 10 million people within five years. The company is expanding its global footprint by establishing the Songdo Global Campus in South Korea as a genome big data hub and opening 'Genome Supermarkets' in Europe. Macrogen leverages partnerships with technology providers like Illumina and PacBio to support its strategy of democratizing access to genomic information across Asia, APAC, Europe, and Latin America.PR NewswireMacrogen Consortium win tender for National Bio Big Data ProjectIllumina was selected as sequencing technology partner for the Macrogen Consortium's National Bio Big Data Project, which will sequence and analyze 145,952 Korean genomes. The project, a pilot since 2020, aims to build a reference genome for 770,000 Koreans by 2028 and 1 million by 2032.